Regulatory News:
Under the liquidity contract signed between Cerenis Therapeutics (Paris:CEREN) and Gilbert Dupont, the following assets were booked to the liquidity account at 31st December 2018:
- Number of shares: 85,203
- Cash balance in the liquidity account: 99,463.14 €
As a reminder, in the last half-year report, at 29th June 2018, the liquidity account stood as follows:
- Number of shares: 85,656
- Cash balance in the liquidity account: 90,256.69 €
About Cerenis Therapeutics
Founded in 2005, Cerenis
Therapeutics is an international biopharmaceutical company dedicated to
the discovery and development of HDL-based innovative therapies.
CERENIS’ expertise has translated into a rich portfolio of programs for
the treatment of cardiovascular disease and associated metabolic
diseases such as NAFLD and NASH as well as a HDL targeted drug delivery
platform in oncology, more specifically in immuno-oncology and
chemotherapy. CERENIS is well positioned to become one of the leaders in
the HDL therapeutic market, with a broad portfolio of programs in
development and several products in clinical phases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190111005383/en/